Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01044251
Other study ID # 22522
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2010
Est. completion date April 17, 2019

Study information

Verified date April 2019
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will analyze the effectiveness of a medication called Frovatriptan, in the context of medication overuse headache (MOH). MOH is a headache that develops when pain-killers are taken frequently. The treatment is to stop the overuse of these pain-killers, but that can sometimes worsen the headache first before it gets better. We are testing Frovatriptan against placebo to see if it can help patients with this transition and avoid the worsening of the headache that can occur. We will also see if Frovatriptan can help in other ways, such as maintain patients free of medication overuse.


Description:

A single-centre, randomized, placebo-controlled trial is proposed to assess Frovatriptan as a transitional therapy in patients diagnosed with medication overuse headache. Currently, there are no proven transitional therapies to help patients get through the detoxification process. Frovatriptan has not been tested as a transitional therapy in the past. This study will compare Frovatriptan, taken over a 10 day transitional period, to placebo. The primary outcome of the study will be the mean headache intensity in the 10 day transitional period in the Frovatriptan group as compared to the placebo group. A number of secondary and exploratory outcomes will also be determined and further data collection will occur at 1, 2, and 3 month periods. The duration of the study for the participants will be 3 months, and they will be asked to keep detailed headache diaries during this time. Ten days of baseline headache diaries will also be performed before patients can enter the study.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date April 17, 2019
Est. primary completion date April 17, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- MOH diagnosed by IHS criteria

- Diagnosis of migraine (with or without aura) in past by IHS criteria

- If patients do not have a baseline diary, then a prospective diary for a 10-day period will be done to confirm medication overuse before study entry.

- Patients aged 18 to 65 years.

- Normal neurological examination.

- Patient is willing and able (in terms of capacity) to sign informed consent.

- Patient is able to understand and complete study protocol, including completion of headache diaries.

- Patient has a stable medical condition.

Exclusion Criteria:

- Headache not meeting IHS criteria for MOH.

- Presence of hemiplegic, basilar, ophthalmoplegic migraine or migrainous infarction.

- Findings on history, neurological exam, or neuroimaging suggestive of secondary causes of headache.

- Post-whiplash or post-traumatic headaches.

- Contraindications to triptans (such as heart disease, peripheral vascular disease or uncontrolled hypertension) or previous serious side effects/intolerance.

- Major psychiatric conditions (such as major depression, bipolar disorder, schizophrenia, addiction), either diagnosed by a physician or positive on standard clinic assessment tools (e.g. BDI questionnaire).

- Major medical conditions or treatments that may interfere with the patient's ability to participate in the study, such as dementia, advanced or terminal cancer, chemotherapy, etc.

- Patient is pregnant, breastfeeding, or is expecting to conceive within the time period of the study. Pregnancy will be determined using a urine test.

- Women of childbearing potential who are not using a reliable method of contraception.

- Patient is a recent user of illicit/recreational drugs or plans to use illicit drugs during the study time period.

- Patient has a recent history of alcohol abuse or dependence, or plans to abuse alcohol during the study duration.

- Patient is unlikely to comply with the study protocol, keep diaries and appointments, or does not have a fixed telephone or address.

- Patient is enrolled in another study or trial that may interfere with their participation or the results of this study.

- Patients with greater than 30% of their data missing during the ten days of baseline diary data collection.

- Patients with mean headache intensities of less than 3 (from a pain scale of 0 to 10, where 0=no pain and 10=pain as bad as possible) during the 10-day baseline period.

- Patients with ongoing Botox treatments or those who have received Botox in the last 4 months.

Study Design


Intervention

Drug:
Frovatriptan
2.5 mg po bid for 10 days
Placebo
1 tab po bid for 10 days

Locations

Country Name City State
Canada South Health Campus Calgary Alberta

Sponsors (2)

Lead Sponsor Collaborator
University of Calgary Alberta Health Services

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Grazzi L, Andrasik F, Usai S, Bussone G. Headache with medication overuse: treatment strategies and proposals of relapse prevention. Neurol Sci. 2008 Apr;29(2):93-8. doi: 10.1007/s10072-008-0867-8. Epub 2008 May 16. Review. — View Citation

Hagen K, Albretsen C, Vilming ST, Salvesen R, Grønning M, Helde G, Gravdahl G, Zwart JA, Stovner LJ. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009 Feb;29(2):221-32. doi: 10.1111/j.1468-2982.2008.01711.x. Epub 2008 Sep 24. — View Citation

Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54. — View Citation

Markus F, Mikko K. Frovatriptan review. Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The mean headache intensity in the 10 day transitional period in the Frovatriptan group as compared to the placebo group. After 10 days of therapy
Secondary The difference in mean headache intensity between the 10 day transitional period and the baseline period. After 10 days of therapy
Secondary The number of day segments with headache of grade 6 or higher during the 10 day transitional period and during days 11-20 of the study. After 10 days and after 20 days
Secondary Number of headache-free days (grade zero) for first two months of study. After 2 months
Secondary Proportion of patients free of medication overuse for first two months of study (i.e. less than 15 days of simple analgesic use or less than 10 days of other analgesic use per month). After 2 months
See also
  Status Clinical Trial Phase
Completed NCT05720819 - Biofeedback-VR for Treatment of Chronic Migraine N/A
Terminated NCT02583425 - Pilot Study of DFN-11 Injection in Medication Overuse Headache Phase 2
Recruiting NCT03655184 - An Observation Study on Neuropsychology and Serum Melatonin Level in Patients With Medication Overuse Headache
Active, not recruiting NCT02993289 - Is Detoxification Needed in Medication-overuse Headache? N/A
Active, not recruiting NCT05608642 - Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment N/A
Recruiting NCT03671681 - Mindfulness Therapy for Chronic Migraine N/A
Completed NCT01078012 - Short Intervention for Medication Overuse Headache (MOH) - Pilot N/A
Completed NCT03767062 - Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches N/A
Recruiting NCT01754571 - CBT in Patients With Medication Overuse Headache Phase 0
Completed NCT02435056 - Medication Overuse Headache (MOH) and an Innovative Approach N/A
Recruiting NCT05452239 - A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Phase 4
Completed NCT00918671 - Medication-overuse Headache: 4 Years Follow up
Completed NCT04336267 - Anodal tDCS in Chronic Migraine With Medication Overuse N/A
Enrolling by invitation NCT01752439 - Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache N/A
Completed NCT00833209 - Orbitofrontal Cortex (OFC) Influence on Addictive Medication Overuse Headache (MOH) Deriving From Migraine N/A
Completed NCT04772742 - Eptinezumab in Adults With Migraine and Medication Overuse Headache Phase 3
Completed NCT04228809 - tDCS in Chronic Migraine With Medication Overuse (Edisom) N/A
Not yet recruiting NCT05334927 - China HeadAche DIsorders RegiStry
Completed NCT04090333 - Endocrinological Profile in Patients With Medication-overuse Headache Before and After Withdrawal Therapy
Recruiting NCT01317992 - Ibudilast in the Treatment of Medication Overuse Headache Phase 1/Phase 2